- ISSN: 2210-299X
- E-ISSN: 2210-3007
HTML
-
oa Therapeutic Potential of Nishamalaki Churna in Diabetes Management: A Phytochemical and Mechanistic Review
- Source: Current Indian Science, Volume 3, Issue 1, Jan 2025, E2210299X387275
-
- 30 Jan 2025
- 22 Apr 2025
- 28 Jul 2025
Abstract
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia and associated complications, including cardiovascular disease, neuropathy, and renal impairment. While conventional therapies such as insulin and oral hypoglycemics manage glycemia, they often fail to address the underlying metabolic disturbances or prevent long-term complications. This has prompted interest in complementary approaches, including traditional herbal formulations.
A comprehensive literature review was conducted across PubMed, Scopus, Google Scholar, and the AYUSH Research Portal for the period 1951–2024. Search terms included ‘Nishamalaki Churna,’ ‘Amla,’ ‘Haridra,’ ‘diabetes,’ ‘oxidative stress,’ and ‘insulin resistance.’ Classical Ayurvedic texts were reviewed alongside experimental and clinical studies. The inclusion criteria encompassed peer-reviewed research on Nishamalaki Churna (NAC) or its components (Emblica officinalis and Curcuma longa) in the context of diabetes.
Amla improves insulin sensitivity and reduces oxidative stress due to its high antioxidant and vitamin C content. Haridra, rich in curcumin, exhibits anti-inflammatory and insulin-sensitizing effects. In combination, NAC demonstrates synergistic action, improving glucose metabolism and metabolic regulation. Preclinical studies report decreased blood glucose and HbA1c, enhanced antioxidant enzyme activity, and inhibition of carbohydrate-digesting enzymes. Clinical trials have revealed improvements in fasting/postprandial glucose levels, lipid profiles, and symptomatic relief, with minimal side effects.
NAC offers a multifaceted therapeutic effect through antioxidant, anti-inflammatory, and metabolic regulatory mechanisms. Its polyherbal composition provides a synergistic approach distinct from single-agent pharmaceuticals. However, challenges in formulation standardization and the need for large-scale clinical validation persist.
NAC holds promise as a safe, complementary intervention in type 2 diabetes management, warranting further clinical investigation.
